Literature DB >> 10694953

Differential DNA methylation of the p16 INK4A/CDKN2A promoter in human oral cancer cells and normal human oral keratinocytes.

D T Cody1, Y Huang, C J Darby, G K Johnson, F E Domann.   

Abstract

The p16 INK4A tumor suppressor gene participates in establishing and maintaining the malignant phenotype of a variety of cancer cell lines and primary tumors. Recently it has been observed that p16 expression is lost in oral cavity cancer cell lines in the presence of a normal intact gene. To examine the role of DNA methylation as an explanation for these findings, we analyzed the DNA methylation patterns of the p16 INK4A promoter in DNA isolated from primary cultures of normal human oral keratinocytes and squamous cell carcinoma (SCC-15) oral cancer cells using bisulfite genomic sequencing. Our results demonstrated striking differences in the methylation status of the 5' CpG island of the p16 gene between normal and cancer cells. Normal human oral keratinocytes showed practically no methylation of the p16 INK4A promoter, while SCC-15 oral cancer cells showed almost complete methylation in this region. These data implicate DNA methylation as a mechanism for transcriptional silencing of the p16 INK4A gene in oral cancer cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10694953     DOI: 10.1016/s1368-8375(99)00026-3

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  10 in total

Review 1.  The Warburg effect: molecular aspects and therapeutic possibilities.

Authors:  Hanh Ngo; Stephanie M Tortorella; Katherine Ververis; Tom C Karagiannis
Journal:  Mol Biol Rep       Date:  2015-04       Impact factor: 2.316

2.  Methylation of the p16(INK4a) promoter region in telomerase immortalized human keratinocytes co-cultured with feeder cells.

Authors:  B W Darbro; K M Lee; N K Nguyen; F E Domann; A J Klingelhutz
Journal:  Oncogene       Date:  2006-06-12       Impact factor: 9.867

3.  Tumor suppression by MEG3 lncRNA in a human pituitary tumor derived cell line.

Authors:  Paweena Chunharojrith; Yuki Nakayama; Xiaobing Jiang; Rachel E Kery; Jun Ma; Cristine S De La Hoz Ulloa; Xun Zhang; Yunli Zhou; Anne Klibanski
Journal:  Mol Cell Endocrinol       Date:  2015-08-15       Impact factor: 4.102

Review 4.  Metabolic defects provide a spark for the epigenetic switch in cancer.

Authors:  Michael J Hitchler; Frederick E Domann
Journal:  Free Radic Biol Med       Date:  2009-04-10       Impact factor: 7.376

Review 5.  Regulation of SOD2 in cancer by histone modifications and CpG methylation: closing the loop between redox biology and epigenetics.

Authors:  Anthony R Cyr; Michael J Hitchler; Frederick E Domann
Journal:  Antioxid Redox Signal       Date:  2012-10-18       Impact factor: 8.401

6.  Methylation-mediated molecular dysregulation in clinical oral malignancy.

Authors:  Rebecca Towle; Cathie Garnis
Journal:  J Oncol       Date:  2012-05-07       Impact factor: 4.375

7.  Epigenetic dysregulation in laryngeal squamous cell carcinoma.

Authors:  Thian-Sze Wong; Wei Gao; Zeng-Hong Li; Jimmy Yu-Wai Chan; Wai-Kuen Ho
Journal:  J Oncol       Date:  2012-05-07       Impact factor: 4.375

Review 8.  Aging and DNA methylation.

Authors:  Marc Jung; Gerd P Pfeifer
Journal:  BMC Biol       Date:  2015-01-31       Impact factor: 7.431

9.  DEK associates with tumor stage and outcome in HPV16 positive oropharyngeal squamous cell carcinoma.

Authors:  Eric A Smith; Bhavna Kumar; Kakajan Komurov; Stephen M Smith; Nicole V Brown; Songzhu Zhao; Pawan Kumar; Theodoros N Teknos; Susanne I Wells
Journal:  Oncotarget       Date:  2017-04-04

Review 10.  A Nexus model of cellular transition in cancer.

Authors:  Mukesh Yadav; Payal Chatterjee; Simran Tolani; Jaya Kulkarni; Meenakshi Mulye; Namrata Chauhan; Aditi Sakhi; Sakshi Gorey
Journal:  Biol Res       Date:  2018-08-07       Impact factor: 5.612

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.